New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Intravitreal anti-vascular epithelial growth factor (VEGF) therapies provide significant anatomical and visual-acuity benefits to patients with neovascular age-related macular degeneration (nAMD ...

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

The management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) continues to evolve through the constant refinement of treatment protocols and ...

The refillable eye implants continuously deliver a customised formulation of a drug over a period of several months. Read ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who ...